Nanna Liebach Lüneborg
Direktor/Vorstandsmitglied bei BIOINVENT INTERNATIONAL AB
Ursprung des Netzwerks ersten Grades von Nanna Liebach Lüneborg
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies.
36
| Private Company | Investment Managers | 36 |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark.
22
| Subsidiary | Financial Conglomerates | 22 |
| Public Company | Biotechnology | 20 | |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark.
13
| Operating Division | Investment Managers | 13 |
| Public Company | Biotechnology | 12 | |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark.
11
| Subsidiary | Pharmaceuticals: Major | 11 |
Numab Therapeutics AG
 Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland.
8
| Holding Company | Miscellaneous Commercial Services | 8 |
Inversago Pharma, Inc.
 Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada.
6
| Subsidiary | Pharmaceuticals: Major | 6 |
Stargazer Pharmaceuticals, Inc.
 Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA.
5
| Holding Company | Pharmaceuticals: Major | 5 |
Glionova AB
 Glionova AB Pharmaceuticals: MajorHealth Technology Glionova AB develops cancer treatment drugs. The firm is a drug discovery and development company. It offers GLN-1001 product. The company was founded by Lars G. J. Hammarström and Patrik Ernfors in 2014 and is headquartered in Stockholm, Sweden.
5
| Private Company | Pharmaceuticals: Major | 5 |
Novo Seeds
 Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark.
4
| Operating Division | Investment Managers | 4 |
Avilex Pharma ApS
 Avilex Pharma ApS Pharmaceuticals: MajorHealth Technology Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark.
4
| Holding Company | Pharmaceuticals: Major | 4 |
Epsilon-3 Bio Ltd
 Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom.
2
| Holding Company | Pharmaceuticals: Other | 2 |
Apposite Capital LLP
 Apposite Capital LLP Investment ManagersFinance Apposite Capital LLP (Apposite Capital) is a private equity arm of Mizuho Financial Group, Inc. founded in 2016 by David Porter. The firm is headquartered in London, United Kingdom.
1
| Subsidiary | Investment Managers | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Nanna Liebach Lüneborg
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| NOVO NORDISK A/S | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Director/Board Member Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal General Counsel | |
| Nyenrode Business Universiteit | College/University | Graduate Degree Undergraduate Degree | |
Academic Medical Center
 Academic Medical Center Hospital/Nursing ManagementHealth Services Academic Medical Center operates a medical center and a medical research facility. It also provides education and training. The company was founded in 1983 and is headquartered in Amsterdam, the Netherlands. | Hospital/Nursing Management | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| ABLIVA AB | Pharmaceuticals: Major | Investor Relations Contact Director/Board Member | |
| EVOTEC SE | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ACTIVE BIOTECH AB | Biotechnology | Public Communications Contact Director/Board Member Chairman | |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Comptroller/Controller/Auditor Corporate Officer/Principal | |
Xention Pharma Ltd.
 Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Pharmaceuticals: Major | Founder Director/Board Member Chief Tech/Sci/R&D Officer Founder | |
| Karolinska Institutet | College/University | Director/Board Member Doctorate Degree Corporate Officer/Principal Graduate Degree | |
| University of Cambridge | College/University | Doctorate Degree Doctorate Degree Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree | |
Cambridge Drug Discovery Holdings Ltd.
 Cambridge Drug Discovery Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Charles River Laboratories International, Inc., Cambridge Drug Discovery Holdings Ltd. is a company that researches potential new drugs for the treatment of cancer. The company is based in Cambridge, UK. Cambridge Drug Discovery Holdings was acquired by Charles River Discovery Research Services UK Ltd., part of Charles River Laboratories International, Inc. from November 14, 2005 on June 11, 2001 for $38 million. The British company was founded by Barry Kenny, Jonathan Mark Treherne. | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer Corporate Officer/Principal | |
| McGill University | College/University | Graduate Degree Doctorate Degree | |
| OREXO AB | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Miscellaneous Commercial Services | Chairman Director/Board Member Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member Founder | |
| Technical University of Denmark | College/University | Graduate Degree Graduate Degree Undergraduate Degree Graduate Degree Graduate Degree | |
| University of Amsterdam | College/University | Doctorate Degree Undergraduate Degree Corporate Officer/Principal | |
| University of Lund | College/University | Undergraduate Degree Masters Business Admin | |
| University of Copenhagen | College/University | Graduate Degree Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Undergraduate Degree | |
| Erasmus University Rotterdam | College/University | Undergraduate Degree Masters Business Admin Graduate Degree | |
| University of Utrecht | College/University | Corporate Officer/Principal Doctorate Degree Graduate Degree Graduate Degree | |
| University of Groningen | College/University | Graduate Degree Graduate Degree Graduate Degree Doctorate Degree Doctorate Degree Graduate Degree | |
| University of Basel | College/University | Corporate Officer/Principal Graduate Degree Doctorate Degree | |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Director/Board Member Chairman General Counsel | |
Ysios Capital Partners SGEIC SA
 Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Investment Managers | Private Equity Investor Private Equity Investor | |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Founder Director/Board Member Director/Board Member | |
Cell Medica Switzerland AG
 Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland. | Pharmaceuticals: Major | Founder Director/Board Member Director/Board Member | |
| MENDUS AB | Biotechnology | Director/Board Member Director/Board Member | |
| UNIQURE N.V. | Biotechnology | Chairman Founder Director/Board Member | |
Prexton Therapeutics SA
 Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Major | Director/Board Member Founder Director/Board Member | |
| Harvard Business School | College/University | Masters Business Admin Corporate Officer/Principal Masters Business Admin | |
SkylineDx BV
 SkylineDx BV Medical/Nursing ServicesHealth Services SkylineDx BV develops molecular diagnostic tests for blood cancers. The firm focuses on the development and commercialization of gene signature-based diagnostic tests, which assist healthcare professionals in making personalized treatment decisions for individual patients. Its products include MMprofiler and AMLprofiler. The company was founded by Dharminder S. Chahal and Bob Löwenberg in 2005 and is headquartered in Rotterdam, the Netherlands. | Medical/Nursing Services | Director of Finance/CFO Director/Board Member | |
| GALECTO, INC. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member Chairman Director/Board Member Chief Operating Officer Director/Board Member Director/Board Member Chief Executive Officer Director/Board Member | |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Founder Chairman Chief Tech/Sci/R&D Officer Director/Board Member Chief Operating Officer Director/Board Member | |
VectorY BV
 VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member Director/Board Member Chairman Corporate Officer/Principal | |
NorthSea Therapeutics BV
 NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
NewAmsterdam Pharma Holding BV
 NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Biotechnology | Chairman Director/Board Member Founder | |
Novo Holdings A/S (Investment Company)
 Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Financial Conglomerates | Chairman Corporate Officer/Principal Chief Executive Officer | |
Complement Therapeutics Ltd.
 Complement Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| ACACIA PHARMA GROUP PLC | Pharmaceuticals: Other | Director/Board Member Chairman | |
Momentum Energy Group A/S
 Momentum Energy Group A/S Electric UtilitiesUtilities Momentum Energy Group A/S is a holding Danish company that provides electricity production services. The private company is based in Roskilde, Denmark and has subsidiaries in Denmark. The CEO of the company is Michael Shalmi. | Electric Utilities | Director/Board Member Chief Executive Officer | |
Momentum Gruppen A/S
 Momentum Gruppen A/S Electric UtilitiesUtilities Momentum Gruppen A/S provides and administrates solar and wind projects. It specializes in procuring, disseminating, and managing solar and wind projects. The firm assists in planning, construction, operational, asset life extension, repowering, decommissioning, and sales and sourcing of projects. The company was founded by Kim Madsen in 2005 and is headquartered in Roskilde, Denmark. | Electric Utilities | Director/Board Member Chairman |
Statistik
International
| Niederlande | 14 |
| Dänemark | 11 |
| Vereinigtes Königreich | 9 |
| Schweden | 8 |
| Vereinigte Staaten | 5 |
Sektoral
| Health Technology | 24 |
| Consumer Services | 14 |
| Commercial Services | 5 |
| Finance | 5 |
| Health Services | 3 |
Operativ
| Director/Board Member | 700 |
| Corporate Officer/Principal | 216 |
| Chairman | 154 |
| Independent Dir/Board Member | 136 |
| Chief Executive Officer | 84 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Gunnar Magnus Modee Persson | 51 |
| Søren Lemonius | 39 |
| James Noble | 39 |
| Martin Edwards | 38 |
| Chau Khuong | 38 |
| Hugo Slootweg | 34 |
| Karen Wilson | 31 |
| Carl Goldfischer | 31 |
| Patrick Volkert Vink | 30 |
| Michael Shalmi | 30 |
| Erez Chimovits | 30 |
| David Grainger | 29 |
| Peter Bisgaard | 28 |
| Michael Hayden | 27 |
| Peter Andersen | 26 |
- Börse
- Insiders
- Nanna Liebach Lüneborg
- Unternehmensverbindungen
